PDF DatasheetHuman Anti-CD45RA Antibody Product Attributes
CD45RA Previously Observed Antibody Staining Patterns
Observed Antibody Staining Data By Tissue Type:
Variations in CD45RA antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in lymphoid tissue in appendix, hematopoietic cells in the bone marrow, germinal center cells in the lymph node, non-germinal center cells in the lymph node, cells in the red pulp in spleen, cells in the white pulp in spleen, germinal center cells in the tonsil and non-germinal center cells in the tonsil. More moderate antibody staining intensity was present in lymphoid tissue in appendix, hematopoietic cells in the bone marrow, germinal center cells in the lymph node, non-germinal center cells in the lymph node, cells in the red pulp in spleen, cells in the white pulp in spleen, germinal center cells in the tonsil and non-germinal center cells in the tonsil. Low, but measureable presence of CD45RA could be seen in. We were unable to detect CD45RA in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of CD45RA expression as measured by anti-CD45RA antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | – | – | – | – | – | – | – | +++ | – | – | – | – | – | – | – | – | – | – |
| PTPRC Variability | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| CD45RA General Information | |
|---|---|
| Alternate Names | |
| Protein tyrosine phosphatase, receptor type, C, PTPRC | |
| Molecular Weight | |
| 205-220kDa | |
| Chromosomal Location | |
| 1q31.3 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | PTPRC |
| Entrez Gene ID | 5788 |
| Ensemble Gene ID | ENSG00000081237, ENSG00000262418 |
| RefSeq Protein Accession(s) | XP_006711537, XP_006711536, XP_006711535, NP_563578, NP_001254727, NP_002829 |
| RefSeq mRNA Accession(s) | XM_006711473, XM_006711474, NM_080921, NM_080922, NM_001267798, NM_002838, XM_006711472, NR_052021 |
| RefSeq Genomic Accession(s) | NG_007730, NC_000001, NW_003315907, NC_018912 |
| UniProt ID(s) | X6R433, A0A0A0MT22, P08575, M9MML4 |
| UniGene ID(s) | X6R433, A0A0A0MT22, P08575, M9MML4 |
| HGNC ID(s) | 9666 |
| Cosmic ID(s) | PTPRC |
| KEGG Gene ID(s) | hsa:5788 |
| PharmGKB ID(s) | PA34011 |
| General Description of CD45RA. | |
| Recognizes a protein of 205kDa-220kDa, identified as CD45RA [Workshop V; Code CD45.38]. CD45RA is isoforms of the human leukocyte common antigen (CD45). Human CD45 contains three exons which encode peptide segments designated A, B, C, respectively. The differential splicing of the exons generates at least five isoforms, ABC, AB, BC, B, O. This antibody reacts with ABC, BC isoforms. CD45RA is expressed on 40-50% of peripheral CD4+ T-cells, 50% of peripheral CD8+ T-cells, B-cells,, leukemic B-cell lines. T-cells expressing CD45RA are naive or virgin T-cells. T-cells expressing CD45RO are memory T-cells. CD45RA, CD45RO define complementary, predominantly non-overlapping populations of resting peripheral T-cells. This MAb is useful in study on the subpopulation of CD4+ or CD8+ T-cells. It can especially be used to differentiate T-cell lymphomas (CD45RO +ve) from B cell lymphomas (CD45RA +ve). | |
There are no reviews yet.